Omeros’ (OMER) “Hold” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Omeros (NASDAQ:OMER) in a report issued on Wednesday morning, AnalystRatings.com reports.

A number of other equities analysts also recently issued reports on OMER. HC Wainwright reaffirmed a buy rating and set a $35.00 price objective on shares of Omeros in a report on Tuesday, November 5th. Wedbush reissued a hold rating and issued a $18.00 price target on shares of Omeros in a report on Monday, October 28th. ValuEngine downgraded shares of Omeros from a buy rating to a hold rating in a report on Wednesday, October 2nd. Zacks Investment Research downgraded shares of Omeros from a buy rating to a hold rating in a report on Wednesday, October 30th. Finally, BidaskClub downgraded shares of Omeros from a sell rating to a strong sell rating in a report on Saturday, October 12th. Three analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. Omeros currently has a consensus rating of Hold and a consensus target price of $25.60.

Omeros stock traded down $0.61 during mid-day trading on Wednesday, hitting $13.20. 525,200 shares of the stock were exchanged, compared to its average volume of 478,581. The stock has a market capitalization of $687.02 million, a price-to-earnings ratio of -5.95 and a beta of 2.78. The firm’s fifty day simple moving average is $15.37 and its two-hundred day simple moving average is $16.90. Omeros has a 12 month low of $10.30 and a 12 month high of $20.92.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.08. The firm had revenue of $29.86 million for the quarter, compared to analysts’ expectations of $27.19 million. Omeros’s revenue was up 547.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.81) earnings per share. On average, analysts forecast that Omeros will post -1.2 earnings per share for the current year.

In related news, Director Thomas J. Cable sold 5,000 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $15.12, for a total value of $75,600.00. Following the transaction, the director now directly owns 35,067 shares of the company’s stock, valued at approximately $530,213.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 12.80% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System raised its stake in Omeros by 2.5% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 32,527 shares of the biopharmaceutical company’s stock valued at $510,000 after acquiring an additional 790 shares during the period. Cambridge Investment Research Advisors Inc. raised its stake in Omeros by 8.5% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 19,593 shares of the biopharmaceutical company’s stock valued at $307,000 after acquiring an additional 1,543 shares during the period. Allianz Asset Management GmbH raised its stake in Omeros by 2.1% in the 2nd quarter. Allianz Asset Management GmbH now owns 76,647 shares of the biopharmaceutical company’s stock valued at $1,203,000 after acquiring an additional 1,603 shares during the period. Sheaff Brock Investment Advisors LLC raised its stake in Omeros by 7.0% in the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 25,680 shares of the biopharmaceutical company’s stock valued at $419,000 after acquiring an additional 1,680 shares during the period. Finally, Swiss National Bank raised its stake in Omeros by 2.2% in the 2nd quarter. Swiss National Bank now owns 86,700 shares of the biopharmaceutical company’s stock valued at $1,360,000 after acquiring an additional 1,900 shares during the period. 53.46% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: What is the Hang Seng index?  

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit